Provenge® (sipuleucel-T)

Starts the Fight and Helps His
Immune System Sustain* It


PROVENGE is immunotherapy for asymptomatic
or minimally symptomatic metastatic castrate
resistant prostate cancer (mCRPC)

Learn More >

At the time of
metastatic diagnosis

of CRPC patients are eligible
for PROVENGE2

Treat Early - make sure your patients
take advantage of the PROVENGE window

Learn More >
  • Enrollment
  • Benefit
    Verification
  • Treatment
    Scheduling
  • Apheresis
    Support
  • Infusion
  • Billing &
    Reimbursement

DENDREON ON CALL – Supporting Your Practice Before, During, And After Treatment

Immunity from hassle – every step of the way

Learn More >

Sustained Immune Response And Short Duration Of Treatment*


Learn More >
View Dr Chardi Nabhan video on Patient Selection

*A sustained immune response was seen out to 26 weeks in the pivotal study (the last time point measured).1

REFERENCES:

  1. Provenge [prescribing information]. Seattle, WA: Dendreon Corporation; 2014.
  2. Data on file. Dendreon Corporation.

This site is intended for US Health Care Professionals only.

INDICATION
PROVENGE® (sipuleucel-T) is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone-refractory) prostate cancer.

IMPORTANT SAFETY INFORMATION

Acute Infusion Reactions: Acute infusion reactions (reported within 1 day of infusion) may occur and include nausea, vomiting, fatigue, fever, rigor or chills, respiratory events (dyspnea, hypoxia, and bronchospasm), syncope, hypotension, hypertension, and tachycardia. Closely monitor patients with cardiac or pulmonary conditions.

Thromboembolic events: Thromboembolic events, including deep venous thrombosis and pulmonary embolism, can occur following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events. PROVENGE should be used with caution in patients with risk factors for thromboembolic events.

Vascular disorders: Cerebrovascular events (hemorrhagic/ischemic strokes and transient ischemic attacks) and cardiovascular disorders (myocardial infarctions) have been reported following infusion of PROVENGE. The clinical significance and causal relationship are uncertain. Most patients had multiple risk factors for these events.

Handling Precautions: PROVENGE is intended solely for autologous use and is not tested for transmissible infectious diseases.

Adverse Reactions: The most common adverse reactions reported in clinical trials (≥ 15% of patients receiving PROVENGE) were chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Please see the Full Prescribing Information.